Hikma Pharmaceuticals Plc’s (HKMPF) “Equal Weight” Rating Reaffirmed at Morgan Stanley
Hikma Pharmaceuticals Plc (OTC:HKMPF)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Morgan Stanley in a research note issued on Tuesday.
Several other analysts have also commented on the stock. ValuEngine raised shares of Hikma Pharmaceuticals Plc from a “hold” rating to a “buy” rating in a research report on Thursday, July 27th. Numis Securities Ltd reissued an “add” rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Finally, Jefferies Group LLC lowered shares of Hikma Pharmaceuticals Plc from a “buy” rating to an “underperform” rating in a research report on Wednesday, May 17th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $27.00.
Shares of Hikma Pharmaceuticals Plc (OTC HKMPF) remained flat at $18.60 during midday trading on Tuesday. The firm has a market cap of $4.48 billion and a price-to-earnings ratio of 28.10. The company’s 50-day moving average is $20.10 and its 200 day moving average is $23.45. Hikma Pharmaceuticals Plc has a one year low of $18.15 and a one year high of $35.00.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.